Acousia Therapeutics is focused on developing innovative small molecule drug candidates aimed at treating sensorineural hearing loss (SNHL), which accounts for over 90% of hearing loss cases. Their approach involves a unique dual mode of action that not only enhances hearing but also protects against further auditory damage. The company is particularly dedicated to addressing the unmet medical needs of patients suffering from various forms of hearing loss, including those induced by chemotherapy, age-related factors, and chronic noise exposure. Their lead candidate, ACOU085, is currently undergoing clinical trials to evaluate its efficacy in preventing cisplatin-induced hearing loss, a common side effect of cancer treatment.

The therapeutic strategy employed by Acousia involves targeting the outer hair cells (OHCs) in the cochlea, which are crucial for sound perception. By modulating the KCNQ4-encoded Kv7.4 potassium channel, ACOU085 aims to provide both acute enhancement of hearing function and long-term protection of these sensory cells. This innovative approach positions Acousia's treatments as potential first-line therapies that could complement existing hearing aids and cochlear implants, thereby improving overall auditory clarity and quality of life for individuals affected by hearing loss.

Germany

Acousia is a pioneer of novel medicines. Founded in 2012, the company’s experienced and entrepreneurial management team is committed to combating hearing loss. Thanks to its exclusive collaboration agreement with the renowned Translational Hearing Research Group of Tuebingen University Clinic and an ecosystem of experts and CROs, Acousia has made significant strides with its advanced small molecule drug candidates.

Acousia Therapeutics

Company Details